What is claimed is:

- 1. A vaccine comprising membrane-bound polypeptide having exposed antigenic determinants capable of raising neutralizing antibodies against a pathogen, said polypeptide being functionally associated with a membrane of a recombinant, stable, continuous cell line capable of its production.
- 2. A vaccine comprising a membrane-free devivative of a membrane-bound polypeptide, having exposed antigenic determinants capable of raising neutralizing antibodies against a pathogen, in which the polypeptide first is formed functionally associated with a membrane of a recombinant stable, continuous cell line capable of its production and then dissolved free from said membrane.
 - 3. A vaccine according to Claim 1 or Claim 2 wherein the recombinant host cell is a stable eukaryotic cell line.
- 4. A vaccine according to Claim 1 or Claim 2 wherein the host cell is a mammalian cell line.
 - 5. A vaccine according to Claim 3 or Claim 4 wherein the cell line is deficient in the production of dihydrofolate reductase (dhfr) and contains an expression vector incorporating a dhfr selectable marker and a gene coding for said polypeptide.
 - 6. A vaccine of Claims 1-5 wherein the polypeptide comprises at least one glycoprotein of herpes simplex virus type 1 or type 2, and said pathogen is herpes simplex virus type 1 and/or type 2.
 - 7. The vaccine of Claim 6 in which said glycoprotein comprises a gD.
 - 8. The vaccine of Claim 6 in which said glycoprotein comprises a gC.

B


15

5

30

25

35



A vaccine comprising a truncated, membrane-free derivative of a membrane-bound polypeptide, said derivative being devoid of membrane-binding domain whereby the derivative polypeptide is free of said membrane, and having exposed antigenie determinants capable of raising neutralizing antibodies against a pathogen.

- 11. A vaccine according to Claim 10 wherein the truncated polypeptide is a derivative of a glycoprotein D of a herpes simplex virus type 1 or type 2 and the pathogen is herpes simplex virus type 1 and/or type 2.
- A vaccine according to Claim 10 wherein the truncated 15 polypeptide is a derivative of a glycoprotein C of a herpes simplex virus type 1 or type 2, and the pathogen is herpes simplex virus type 1 and/or type 2.

13. A vaccine according to Claim 11 wherein the truncated derivative comprises the N-terminal region of gD polypeptide up to about amino acid residue 300.

14. A method of producing a paccine according to any one of Claim 10 to 13 wherein DNA encodin $\frac{\mu}{2}$ said membrane-bound polypeptide is prepared lacking coding for/membrane-binding domain, incorporating the DNA into an expression/vector, transfecting a host cell with said vector, and collecting the truncated polypeptide as a secretion product.

15. A method according to Claim 14 wherein the transfected host cell is a stable eukaryotid cell line.

216

16. A method according to Claim 15 wherein the transfected host

cell is a mammalián cell lihe. 35

Subiti

SW

Sab. Ha

217

1. A method according to Claim 15 or Claim 16 wherein the cell line is deficient in the production of dhfr and the vector contains a dhfr selectable marker.

18. A method according to any one of Claims 14 to 16 wherein the truncated polypeptide is a glycoprotein D of herpes simplex virus type 1 or type 2.

19. A method according to Claim 18 wherein the truncated polypeptide is restricted to the first 300 amino acid residues of the glycoprotein D.

15

10

20

add Hy

35

25

57